Vaccine ETF Penghua (159657) up over 1.3%, biotech and pharmaceuticals surged strongly in the early trading session

The biopharmaceutical sector surged in early trading. On the news front, the world’s first hexavalent rotavirus vaccine has started its first dose vaccination in Shanghai. Public information shows that this globally launched vaccine was independently developed by the Wuhan Institute of Biological Products of China National Pharmaceutical Group and officially received approval from the National Medical Products Administration for market launch in August 2025. It is intended for the prevention of acute gastroenteritis in infants and young children caused by rotavirus serotypes G1, G2, G3, G4, G8, and G9.

Zhongyou Securities pointed out that overseas CXO orders are showing a structurally recovering trend, particularly with preclinical and clinical CRO order indicators significantly improving in the second half of 2025. CDMO continues to maintain strong growth momentum, with leading companies like LONZA, Fujifilm, and Bachem ramping up production capacity for emerging drug types such as ADCs, peptides, and oligonucleotides. This trend reflects a resurgence in global innovative drug research and development, combined with domestic vaccine technology platforms (such as mRNA and viral vectors) accelerating overseas validation, which is expected to drive marginal increases in upstream vaccine R&D services and clinical trial support demand.

As of March 24, 2026, 11:30 AM, the Guozheng Vaccine and Biotechnology Index (980015) rose sharply by 1.31%, with component stocks such as WuXi AppTec increasing by 6.09%, Dizal Pharmaceutical by 5.01%, Junshi Biosciences by 4.15%, and other stocks like Rongchang Bio and Kelun also following suit. The Vaccine ETF Penghua (159657) increased by 1.39%, with the latest price at 0.58 yuan.

The Vaccine ETF Penghua closely tracks the Guozheng Vaccine and Biotechnology Index, which consists of 50 securities involved in the biotechnology industry, reflecting the overall performance of high-quality listed companies in the biotechnology sector on the Shanghai, Shenzhen, and Beijing exchanges.

Data shows that as of February 27, 2026, the top ten weighted stocks in the Guozheng Vaccine and Biotechnology Index (980015) are Fosun Pharma, Changchun High-tech, Watson Bio, Zhifei Biological Products, Hualan Biological Engineering, Zhaoyan New Drug, Wantai Biological Pharmacy, Livzon Pharmaceutical Group, Liaoning Chengda, and Kangtai Biological Products, with the top ten stocks collectively accounting for 65.01%.

Vaccine ETF Penghua (159657), off-market connections (A: 021292; C: 021293; I: 022794).

Massive information and precise interpretations are all available on the Sina Finance APP.